US Patent:
20110098309, Apr 28, 2011
Inventors:
Gary Charles Look - Santa Clara CA, US
Lauri Schultz - Batavia IL, US
Alexandre Mikhaylovich Polozov - Naperville IL, US
Nikhil Bhagat - Aurora IL, US
Jian Wang - San Diego CA, US
David E. Zembower - La Grange IL, US
William F. Goure - Livermore CA, US
Todd Pray - San Mateo CA, US
Grant A. Krafft - Glenview IL, US
Assignee:
ACUMEN PHARMACEUTICALS, INC. - Livermore CA
International Classification:
A61K 31/4965
C12N 5/071
A61K 31/16
A61K 31/343
A61K 31/341
A61K 31/381
A61K 31/40
C07C 233/00
C07D 333/56
C07D 333/22
C07D 207/30
C07D 241/04
C07D 307/02
A61P 25/28
US Classification:
51425501, 435325, 514614, 514448, 514461, 514443, 514408, 564123, 549 49, 549 70, 548563, 544391, 549483
Abstract:
Disclosed are methods of inhibiting, regulating, and/or modulating the formation of soluble, globular, non-fibrillar, neurotoxic amyloid β1-42 oligomers from amyloid β1-42 monomers using acylhydrazide compounds. Also disclosed are methods of treating a patient suffering from diseases associated with the formation of soluble, globular, non-fibrillar, neurotoxic amyloid β1-42 oligomers using acylhydrazide compounds.